The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 06, 2015

Filed:

Sep. 13, 2013
Applicant:

Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;

Inventors:

Tsuyoshi Soneda, Kanagawa, JP;

Hiroshi Takeshita, Chiba, JP;

Yoshiko Kagoshima, Tokyo, JP;

Yuko Yamamoto, Tokyo, JP;

Takafumi Hosokawa, Tokyo, JP;

Toshiyuki Konosu, Kanagawa, JP;

Nobuhisa Masuda, Tokyo, JP;

Takuya Uchida, Tokyo, JP;

Issei Achiwa, Chiba, JP;

Junichi Kuroyanagi, Chiba, JP;

Tetsunori Fujisawa, Tokyo, JP;

Aki Yokomizo, Chiba, JP;

Tetsuji Noguchi, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 233/90 (2006.01); C07D 413/14 (2006.01); C07D 495/16 (2006.01); C07D 487/04 (2006.01); C07D 233/66 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 487/06 (2006.01); C07D 487/12 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); C07D 233/66 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 487/06 (2013.01); C07D 487/12 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01); C07D 233/90 (2013.01); C07D 413/14 (2013.01); C07D 495/16 (2013.01);
Abstract

To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.


Find Patent Forward Citations

Loading…